Mortality rate among HIV-positive children on ART in Northwest Ethiopia: a historical cohort study.
ART
Amhara region
Ethiopia
HIV-positive
Mortality
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
27 Aug 2020
27 Aug 2020
Historique:
received:
17
05
2019
accepted:
20
08
2020
entrez:
29
8
2020
pubmed:
29
8
2020
medline:
16
12
2020
Statut:
epublish
Résumé
Though highly active antiretroviral therapy (HAART) has been available for more than a decade in Ethiopia, information regarding mortality rates of human immunodeficiency virus (HIV)-positive children after antiretroviral therapy antiretroviral therapy (ART) initiation is very scarce. Thus, this study intends to determine the predictors of mortality among HIV-positive children receiving ART in Amhara Region. A multicenter facility-based historical cohort study was conducted in 538 HIV-positive children on ART from January 2012 to February 2017. We employed a standardized data extraction tool, adapted from ART entry and follow-up forms. Descriptive analyses were summarized using the Kaplan-Meier survival curve and log rank test. Then, the Cox-proportional hazard regression model was employed to estimate the hazard of death up to five-years after ART initiation. Variables with p-values ≤0.25 in bivariable analysis were candidates to the multivariable analysis. Finally, variables with p-values < 0.05 were considered as significant variables. The cohort contributed a total follow-up time of 14,600 child-months, with an overall mortality rate of 3.2 (95% CI: 2.3, 4.3) per 100 child-years. This study also indicated that HIV-infected children presenting with opportunistic infections (OIs) (AHR: 2.5, 95% CI: 1.04, 5.9), anemia (AHR: 3.1, 95% CI: 1.4, 6.7), severe immunodeficiency (AHR: 4.4, 95% CI: 1.7, 11.7), severe stunting (AHR: 3.3, 95% CI: 1.4, 8.0), severe wasting (AHR: 3.1, 95% CI: 1.3, 7.3), and advanced disease staging (III and IV) (AHR: 3.0, 95% CI: 1.2, 7.1) were at higher risk of mortality. A higher rate of mortality was observed in our study as compared to previous Ethiopian studies. HIV-positive children presenting with anemia, OIs, severe immunodeficiency, advanced disease staging (III and IV), severe stunting, and severe wasting were at higher risk of mortality.
Sections du résumé
BACKGROUND
BACKGROUND
Though highly active antiretroviral therapy (HAART) has been available for more than a decade in Ethiopia, information regarding mortality rates of human immunodeficiency virus (HIV)-positive children after antiretroviral therapy antiretroviral therapy (ART) initiation is very scarce. Thus, this study intends to determine the predictors of mortality among HIV-positive children receiving ART in Amhara Region.
METHODS
METHODS
A multicenter facility-based historical cohort study was conducted in 538 HIV-positive children on ART from January 2012 to February 2017. We employed a standardized data extraction tool, adapted from ART entry and follow-up forms. Descriptive analyses were summarized using the Kaplan-Meier survival curve and log rank test. Then, the Cox-proportional hazard regression model was employed to estimate the hazard of death up to five-years after ART initiation. Variables with p-values ≤0.25 in bivariable analysis were candidates to the multivariable analysis. Finally, variables with p-values < 0.05 were considered as significant variables.
RESULTS
RESULTS
The cohort contributed a total follow-up time of 14,600 child-months, with an overall mortality rate of 3.2 (95% CI: 2.3, 4.3) per 100 child-years. This study also indicated that HIV-infected children presenting with opportunistic infections (OIs) (AHR: 2.5, 95% CI: 1.04, 5.9), anemia (AHR: 3.1, 95% CI: 1.4, 6.7), severe immunodeficiency (AHR: 4.4, 95% CI: 1.7, 11.7), severe stunting (AHR: 3.3, 95% CI: 1.4, 8.0), severe wasting (AHR: 3.1, 95% CI: 1.3, 7.3), and advanced disease staging (III and IV) (AHR: 3.0, 95% CI: 1.2, 7.1) were at higher risk of mortality.
CONCLUSION
CONCLUSIONS
A higher rate of mortality was observed in our study as compared to previous Ethiopian studies. HIV-positive children presenting with anemia, OIs, severe immunodeficiency, advanced disease staging (III and IV), severe stunting, and severe wasting were at higher risk of mortality.
Identifiants
pubmed: 32854692
doi: 10.1186/s12889-020-09418-6
pii: 10.1186/s12889-020-09418-6
pmc: PMC7457276
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1303Références
Ethiop Med J. 2010 Jan;48(1):1-10
pubmed: 20607992
BMC Pediatr. 2012 Oct 08;12:161
pubmed: 23043325
AIDS Care. 2015;27(6):723-30
pubmed: 25599414
J Int Assoc Provid AIDS Care. 2015 Mar-Apr;14(2):172-9
pubmed: 24106055
Adv Med. 2018 Jun 19;2018:6409134
pubmed: 30018988
Am J Respir Crit Care Med. 2003 Jun 1;167(11):1472-7
pubmed: 12569078
Pediatr Infect Dis J. 2014 Nov;33(11):1148-55
pubmed: 24945879
Med Mal Infect. 2017 Feb;47(1):32-37
pubmed: 27609595
BMC Pediatr. 2010 May 18;10:33
pubmed: 20482796
Arch Public Health. 2013 Jun 08;71(1):13
pubmed: 23759075
Int J Tuberc Lung Dis. 2013 Nov;17(11):1389-95
pubmed: 24125439
Pediatrics. 2012 Sep;130(3):e591-9
pubmed: 22891234
PLoS One. 2011;6(7):e22706
pubmed: 21829487
Blood. 1998 Jan 1;91(1):301-8
pubmed: 9414298
PLoS One. 2011;6(12):e29294
pubmed: 22216237
AIDS. 1999 May 28;13(8):943-50
pubmed: 10371175
J Paediatr Child Health. 2015 Feb;51(2):204-8
pubmed: 25142757
BMC Public Health. 2019 Jan 28;19(1):115
pubmed: 30691416
BMC Public Health. 2013 Nov 06;13:1047
pubmed: 24517533
J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):464-70
pubmed: 16010171
J Pediatr Gastroenterol Nutr. 2013 Aug;57(2):258-64
pubmed: 23880630
Mem Inst Oswaldo Cruz. 2012 Jun;107(4):532-8
pubmed: 22666865
Indian Pediatr. 2018 Apr 15;55(4):301-305
pubmed: 29428912
SAGE Open Med. 2019 Mar 25;7:2050312119838957
pubmed: 30937168
PLoS One. 2014 Dec 08;9(12):e113095
pubmed: 25485634